Amarillo Biosciences Issues Corporate Update

AMARILLO, Texas, Oct. 14, 2011 /PRNewswire/ -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today provided an update on company activities.

Oral Interferon Phase 2 Hepatitis C Study Nearing Completion

ABI's oral interferon research continues. Results from a Phase 2, dose-ranging study of oral interferon for the prevention of relapse in hepatitis C patients are expected in the first quarter of 2012. A Phase 2 study of oral IFN, in combination with Tamiflu, for the treatment of influenza infection will be conducted during the upcoming flu season in Taiwan. Results are expected in the third quarter of 2012.

New Oral Interferon Studies Planned in Hepatitis B and Cancer

Two new oral interferon studies are expected to start in 2012. The first will be a Phase 2 study for treatment and prevention of relapse in patients with chronic hepatitis B infection. The second will be a pilot trial to evaluate oral interferon as adjunctive therapy for certain types of cancer.

Launch of Product to Enhance Health of Animals in Shelters Planned by Year's End

There are approximately 3,500 animal shelters in the United States. Whenever animals from different sources and backgrounds, and often with an incomplete vaccination history, are placed into these shelters, upper respiratory illness (URI) with severe cough and fever is a common occurrence. Digestive tract infections also frequently develop in these shelters. Both URI and diarrhea cause severe illness and an unacceptably high rate of death in sheltered animals.

ABI's goal is to provide a product to help address these common health problems afflicting the nation's animal shelters. More than 20 years of research and observations have resulted in the creation of an inexpensive oral formulation that can be given to companion animals upon arrival at shelters to improve their health and enhance their immunity. Product launch is expected by the end of the year.

About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza and hepatitis C. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures about Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2010.

SOURCE Amarillo Biosciences, Inc.